MOSCOW, September 13 (RAPSI) – The Tenth Commercial Court of Appeals has upheld a lower court’s ruling dismissing a lawsuit against Russian Nativa company filed by an Irish subsidiary of the U.S. drug corporation Bristol-Myers Squibb International Holdings, which sought to prohibit production of a medicine, the court ruling reads.

On July 4, the Moscow Regional Court dismissed the lawsuit.

According to the plaintiff, production of dasatinib drug by the defendant may violate its patent rights.

The court, however, ruled that Nativa did not violate the plaintiff’s exclusive rights and refused to grant the lawsuit.

Nativa CEO Alexander Malin said that foreign companies persisted in their attempts to hinder the activity of Russian production enterprises. He added that Nativa is involved in court proceedings concerning patent disputes with largest international corporations and has already won six of them.

Nativa is a Russian pharmaceutical company specializing in research and production of medicine used in pulmonology, endocrinology, oncology, gynecology and neurology.